The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jul. 14, 2020

Filed:

Jun. 08, 2016
Applicant:

Oncotherapy Science, Inc., Kanagawa, JP;

Inventors:

Takuya Tsunoda, Kanagawa, JP;

Ryuji Ohsawa, Kanagawa, JP;

Sachiko Yoshimura, Kanagawa, JP;

Assignee:

ONCOTHERAPY SCIENCE, INC., Kawasaki-shi, Kanagawa, JP;

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 39/00 (2006.01); C07K 14/47 (2006.01); C12N 5/0783 (2010.01); C07K 7/06 (2006.01); A61K 38/00 (2006.01);
U.S. Cl.
CPC ...
C07K 14/4748 (2013.01); A61K 39/0011 (2013.01); C07K 14/47 (2013.01); C12N 5/0638 (2013.01); A61K 38/00 (2013.01); A61K 39/00 (2013.01); A61K 2039/5154 (2013.01); A61K 2039/53 (2013.01); A61K 2039/572 (2013.01); A61K 2039/575 (2013.01);
Abstract

Peptide vaccines against cancer are described herein. In particular, the present invention describes epitope peptides derived from CDCA1 that elicit CTLs. The present invention also provides established CTLs that specifically recognize HLA-A24 positive target cells pulsed with the peptides. Antigen-presenting cells and exosomes that present any of the peptides, as well as methods for inducing antigen-presenting cells are also provided. The present invention further provides pharmaceutical agents containing the CDCA1 polypeptides or polynucleotides encoding thereof, as well as exosomes and antigen-presenting cells as active ingredients. Furthermore, the present invention provides methods for treating and/or prophylaxis of (i.e., preventing) cancers (tumors), and/or prevention of postoperative recurrence thereof, as well as methods for inducing CTLs, methods for inducing anti-tumor immunity, using the CDCA1 polypeptides, polynucleotides encoding the polypeptides, exosomes or antigen-presenting cells presenting the polypeptides, or the pharmaceutical agents of the present invention. The cancers to be targeted include, but are not limited to, breast cancer, bladder cancer, esophageal cancer, small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC).


Find Patent Forward Citations

Loading…